Jupiter Neurosciences announced it has entered into two financing agreements providing access to up to $20 million in capital to advance its drug development programs and operational goals. According to the company, the flexible funding structure is intended to offer long-term financial support while minimizing dilution for shareholders.
The company said that the financing includes a purchase agreement for up to $10 million of common stock with White Lion Capital and a separate equity line of credit for up to $10 million with an institutional investor. The agreements allow Jupiter Neurosciences to draw capital at its discretion over time, depending on market conditions and company needs.
According to Jupiter Neurosciences, the funds will primarily be used to accelerate the clinical development of its lead candidate, JOTROL, a novel resveratrol-based oral therapeutic designed to treat neuroinflammatory and neurodegenerative conditions such as mild cognitive impairment, Alzheimer’s disease, and rare pediatric disorders. The company said the financing will also help strengthen its balance sheet and support general corporate purposes.
Jupiter Neurosciences claims that the flexibility of the agreements provides a strategic advantage by granting access to capital without relying on traditional debt financing. The company stated that this approach aligns with its long-term objective of advancing JOTROL through regulatory milestones and preparing for subsequent clinical phases.
The company added that the funding agreements position Jupiter Neurosciences to pursue continued growth and clinical progress while maintaining financial stability in a challenging biotech capital market.
